Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 4/20 | 0.36 |
| ▸ | ERAP2 | Q6P179 | 4/20 | 0.36 |
| ▸ | ERAP1 | Q9NZ08 | 4/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.33 |
| ▸ | LAP3 | P28838 | 1/20 | 0.32 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4989853 | 0.91 | GRIK1 (0.40) | ANPEPERAP2ERAP1PTGS2CYP3A4 | |
| SCHEMBL4985219 | 0.87 | ANPEP (0.45) | ANPEPERAP2ERAP1PTGS2GRIK1 | |
| SCHEMBL4989063 | 0.86 | ANPEP (0.35) | ANPEPERAP2ERAP1FOLH1HSP90AB1 | |
| SCHEMBL4994531 | 0.86 | ANPEP (0.51) | ANPEPERAP2ERAP1GRIK1 | |
| SCHEMBL4984115 | 0.85 | ANPEP (0.32) | ANPEPERAP2ERAP1GRIK1SLC1A3 | |
| SCHEMBL4983789 | 0.85 | ANPEP (0.45) | ANPEPERAP2ERAP1FOLH1GRIK1 | |
| SCHEMBL4987793 | 0.84 | PTGS2 (0.36) | ANPEPERAP2ERAP1PTGS2CYP3A4 | |
| SCHEMBL4986128 | 0.84 | PTPN1 (0.33) | ANPEPERAP2ERAP1CYP3A4SLC1A3 | |
| SCHEMBL3994953 | 0.83 | GRIK1 (0.50) | ANPEPERAP2ERAP1GRIK1LAP3 | |
| SCHEMBL3994985 | 0.83 | GRIK1 (0.50) | ANPEPERAP2ERAP1GRIK1LAP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-06-09 | — | — | US | claimed |
| US-7388023-B2 | Amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2008-06-17 | — | — | US | disclosed |
| US-20070129550-A1 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | WANER-LAMBERT COMPANY LLC (US) | 2007-06-07 | — | — | US | disclosed |
| US-7179934-B2 | Amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2007-02-20 | — | — | US | disclosed |
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-06-09 | — | — | US | disclosed |
| US-20050101643-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | SCN2A, SCN1A, OPRD1 | ANPEP 750/4885ERAP2 802/4885ERAP1 1331/4885 |
| US-20070129550-A1 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | SCN2A, OPRD1, SCN1A | ANPEP 691/4885ERAP2 655/4885ERAP1 1085/4885 |
| US-20050101643-A1 | Amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | ANPEP 644/4885ERAP2 731/4885ERAP1 1300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.